

TOUJEO (INSULIN GLARGINE 300 U/ML)

Toujeo SoloStar pre-filled pen contains 450 units in 1.5 mL

Toujeo DoubleStar pre-filled pen contains 900 units in 3 mL

GUIDE FOR HEALTHCARE PROFESSIONALS

- This document is supplied only as a guide to avoid medication errors. Please refer to the Physician Prescribing Information before prescribing and dispensing a Toujeo pen.
- Please provide your patients with the Patient Guide prior to prescribing or dispensing Toujeo for the first time or when switching to a new pen to ensure that your patients and their carers are adequately informed on how to use Toujeo to help reduce the risk of medication errors.


Important information on adjustments during the initial weeks when prescribing Toujeo

Switch between insulin glargine 100 units/mL and Toujeo


- Insulin glargine 100 U/mL and Toujeo (insulin glargine 300 U/mL) are not bioequivalent and are therefore not directly interchangeable.
- Dose adjustment may be needed when patients are switched to an insulin with a different strength.
- Toujeo dose regimen (dose and timing) should be adjusted according to individual response to treatment.
- When switching from insulin glargine 100 units/mL to Toujeo, this can be done on a unit-to-unit basis, but a higher Toujeo dose (approximately 10-18%) may be needed to achieve target ranges for plasma glucose levels.

Toujeo (insulin glargine 300 U/mL) is available in two different presentations:

Toujeo SoloStar
(1.5 mL prefilled pen/450 U)



Toujeo DoubleStar
(3 mL prefilled pen/900 U)



The dose increment in Toujeo SoloStar is 1 U and the dose increment in Toujeo DoubleStar is 2 U.

The dose delivered is the one shown in the dose window.

Switch from other basal insulins to Toujeo

- When switching from a treatment regimen with an intermediate or long-acting insulin product to a regimen with Toujeo 300 U/mL, a change in the dose of the basal insulin may be required and the concomitant anti-hyperglycaemic treatment may need to be adjusted. Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter.
- **Switching from once-daily basal insulins to once-daily Toujeo** can be done unit-to-unit based on previous dose.
- **Switching from twice-daily basal insulins to once-daily Toujeo**, the recommended initial Toujeo dose is 80% of the total daily dose of basal insulin that is being discontinued.
- Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter.

Switch from Toujeo to other basal insulins

- Switching from Toujeo (insulin glargine 300 U/mL) to insulin glargine 100 U/mL results in an increased risk of hypoglycaemic events, mainly in the first week after the switch.
- To reduce the risk of hypoglycaemia, patients who are changing their basal insulin regimen from an insulin regimen with once daily Toujeo to a once daily regimen with Lantus should reduce their dose by 20%.

Refer to Toujeo Physician Prescribing Information for extended prescribing recommendations.

Give a Patient Guide to your patient and recommend he/she must read it carefully, as well as the Instructions for Use leaflet provided in the Toujeo packaging.

This guide, format and content have been approved by the Ministry of Health on Sep 2023.

Reporting adverse events:

Please report medication errors or any side effects suspected to be associated with the use of the Toujeo pen to Ministry of Health using an online form: <https://sideeffects.health.gov.il/> and to Sanofi, by telephone on 09-8633081